Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 7Recruiting 3Withdrawn 1Suspended 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2Lymphoid 2Thoracic 1NET 1Myeloid 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 4Ovarian Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Skin Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Pleural Effusion, Malignant 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Neuroblastoma 2Myelodysplastic Syndromes 2Mesothelioma, Malignant 2Leukemia, Myeloid 2Leukemia 2Hematologic Neoplasms 2Carcinoma, Merkel Cell 2Anus Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × aldesleukin × Clear all
NCT06904066 2026-06-05

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
86 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Indapta Therapeutics, INC.

Phase 1/2 Recruiting
128 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡